|
Originally published In Press as doi:10.1074/jbc.M109408200 on March 19, 2002
J. Biol. Chem., Vol. 277, Issue 21, 18687-18693, May 24, 2002
Ubiquitous 9-O-Acetylation of Sialoglycoproteins
Restricted to the Golgi Complex*
Eric
Dumermuth,
Nicole
Beuret,
Martin
Spiess , and
Pascal
Crottet
From the Biozentrum, University of Basel, Klingelbergstrasse 70, CH-4056 Basel, Switzerland
Received for publication, September 28, 2001, and in revised form, March 14, 2002
 |
ABSTRACT |
9-O-Acetylation of sialic acid is
known as a cell type-specific modification of secretory and plasma
membrane glycoconjugates of higher vertebrates with important functions
in modulating cell-cell recognition. Using a recombinant probe derived
from influenza C virus hemagglutinin, we discovered
9-O-acetylated protein in the Golgi complex of various cell
lines, most of which did not display 9-O-acetylated sialic
acid on the cell surface. All cell lines expressed a sulfated
glycoprotein of 50 kDa (sgp50) carrying 9-O-acetylated
sialic acids, which was used as a model substrate. Like gp40, the major
receptor for influenza C virus of Madin-Darby canine kidney I cells,
sgp50 is 9-O-acetylated on O-linked glycans. However, gp40 was not 9-O-acetylated when expressed in
Madin-Darby canine kidney II or COS-7 cells. The results demonstrate
the existence of two 9-O-acetylation machineries for
O-glycosylated proteins with distinct substrate
specificities. The widespread occurrence of
9-O-acetylated protein in the Golgi furthermore suggests an additional intracellular role for this modification.
 |
INTRODUCTION |
Sialic acids constitute a family of acidic monosaccharides
typically found at terminal positions of glycoconjugates. Their diversity is mainly the result of enzymatic acetylation of hydroxyl groups at carbons 4, 7, 8, and 9 (1). 9-O-Acetylation is the most prevalent modification of sialic acids of glycoproteins and gangliosides in higher vertebrates. It is a tissue-specific and tightly
regulated modification involved in various important processes such as
cell-cell interaction and development (2-4). For example, binding of
the B-cell adhesion molecule Siglec-2 (CD22 ) to sialylated ligands
on the surface of thymocytes is inhibited by 9-O-acetylation (5). Furthermore, 9-O-acetylation was found to be crucial at the two-cell stage of murine development and later in the organization of the retina (6). 9-O-Acetyl sialic acid also serves as the receptor for influenza C virus (7), a group of corona viruses (8), and
hemagglutinating encephalomyelitis virus (9) and thus appears to be a
major determinant of their cell tropism (10).
O-Acetyl transferases for sialic acids have resisted
purification or cloning thus far. However, their activity was localized to the trans side of the Golgi apparatus (11). By
"freeze-frame" analysis with isolated membranes of rat hepatocytes,
9-O-acetylation was shown to occur in a compartment of the
trans-Golgi network separate from that of sialylation and
galactosylation (11). In this system, 9-O-acetylation was
enriched on membrane-bound but not soluble cargo proteins leaving the
trans-Golgi network.
9-O-Acetylation is specific for only a subset of
sialoglycoproteins expressed in a given cell type, indicating that
substrate recognition by 9-O-acetyl transferase(s) extends
beyond the sialic acid itself. The 9-O-acetylation patterns
of different cell types are thus likely to be the result of
differential expression of substrates and/or transferase(s). Very few
protein substrates for 9-O-acetylation of sialic acids have
been identified at the molecular level, and all of them are
sialomucins: bovine submaxillary mucin, CD43 and CD45RB of T
lymphocytes (12), and gp40, the major receptor of influenza C virus in
Madin-Darby canine kidney (MDCK)1 type I cells (13,
14).
Influenza C virus was found to be extremely useful in detecting and
characterizing 9-O-acetylated sialoglycoproteins and
gangliosides. The viral 9-O-acetyl sialic acid binding
activity (the hemagglutinin, H) is part of a multifunctional spike
protein, HEF, which also contains a receptor destroying acetylesterase
activity (E) and a fusion function (F) (15). The entire virus has been
used to detect 9-O-acetyl sialic acid in tissues and cell
lines and on Western blots (13, 14, 16-19). In addition, a chimeric
protein, CHE-Fc, consisting of the influenza C virus
hemagglutinin-esterase domains fused to the Fc region of human IgG1,
was constructed as a specific tool for the detection of
9-O-acetylated sialoglycoconjugates in histochemistry,
Western blots, thin-layer chromatography overlays (20), enzyme-linked
immunosorbent assay, flow cytometry (12), and even immunogold electron
microscopy (11).
Here, we have used CHE-Fc as a probe to analyze the subcellular
distribution of 9-O-acetylated glycoproteins in a variety of
cell lines by fluorescence microscopy. We discovered that all cell
lines tested, including some that were previously shown to be resistant
to infection by influenza C virus and considered to lack
9-O-acetyl sialic acid, stained positive intracellularly in
the Golgi apparatus. A sulfated glycoprotein of 50 kDa could be
precipitated by CHE-Fc in all cases and was useful as a model substrate
of this ubiquitous, intracellular 9-O-acetylation. Our results indicate that differential 9-O-acetylation patterns
in various cell types depend on differences in both the substrates and
the acetylation machineries.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
MDCK I cells were obtained from G. Herrler
(Tierärztliche Hochschule, Hannover, Germany), and calf primary
aortic endothelial cells were obtained from K. Fiedler (Biozentrum,
Universität Basel, Basel, Switzerland). These cell lines, as well
as MDCK II, COS-1, CaCo2, HepG2, HEK-293, HeLa, NIH-3T3, BHK-21,
CHO-K1, and CHO-Lec1 cells, were grown in Eagle's minimal essential
medium or Dulbecco's modified minimal essential medium with 10% fetal calf serum at 37 °C with 7.5% CO2. The media were
supplemented with 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.
CHE-Fc Production--
CHE-Fc, the chimera of influenza C virus
hemagglutinin-esterase and the Fc region of human IgG, was produced by
stably transfected HEK-293 cells provided by A. Varki (University of
California, San Diego, CA). The cells were adapted to the protein-free
medium CHO-S-SFM II (Invitrogen) and grown in a CELLine CL 350 device (Integra Bioscience). Conditioned medium was collected twice a week and
kept at 4 °C until purification. CHE-Fc was isolated using protein
A-Sepharose as described previously (20). The probe was concentrated by
centrifugation in a Centricon-50 filter device (Amicon). To inactivate
the esterase activity, CHE-Fc was incubated on ice for 30 min with 1 mM diisopropyl fluorophosphate, producing CHE-FcD. To
improve the binding efficiency of the probe, inactivation was repeated,
followed by dialysis against PBS. CHE-FcD was stable at 4 °C for
several months.
Immunofluorescence--
For indirect immunofluorescence
staining, cells were grown on 14-mm glass coverslips, fixed with PBS
containing 3% paraformaldehyde for 20 min at room temperature, washed
in PBS, and quenched with 50 mM NH4Cl in PBS.
To permeabilize the cells, the cells were then incubated with 0.1%
Triton X-100 for 10 min at room temperature. Alternatively, cells were
fixed with methanol and acetone according to Schwarz and Futerman (21),
i.e. using conditions shown to extract glycolipids.
Nonspecific antibody binding was blocked with PBS containing 1% bovine
serum albumin and 10% goat serum (PBSB). The fixed cells were
incubated with 10 µg/ml CHE-FcD in PBSB for 1 h, washed with
PBSB, and incubated with fluorescein isothiocyanate-labeled anti-human
immunoglobulin secondary antibody diluted 1:400 in PBSB for 30 min.
After additional washes with PBSB, PBS, and water, the coverslips were
mounted in Mowiol 4-88 (Hoechst) containing 2.5% 1,4-diazobicyclo-
(2,2,2)-octane and analyzed using a Zeiss Axiophot microscope. For
double immunofluorescence, the fixed cells were also incubated with
mouse monoclonal antibodies against giantin (a gift from H.-P. Hauri,
Biozentrum) followed by incubation with Cy3-labeled anti-mouse IgG
secondary antibodies.
Western Blot Analysis--
Cell lysates were split in two
halves, one of which was incubated with 0.1 M NaOH for 15 min at 37 °C and neutralized with HCl. Both samples were then
separated by SDS-PAGE and electroblotted onto polyvinylidene
difluoride membrane (Millipore). The membrane was blocked with 5%
bovine serum albumin in PBS and incubated at 4 °C with 3 µg/ml
CHE-FcD in PBS/1% bovine serum albumin. After several washes in
PBS/0.05% Tween 20, horseradish peroxidase-conjugated anti-human IgG
was added in PBS/1% bovine serum albumin. The blot was developed using
the enhanced chemiluminescence kit from Amersham Biosciences.
Construction and Expression of gp40HMY--
To aid
characterization, gp40 (provided by G. Herrler) was fused to the
tag sequence HMY, which is composed of a His6 sequence for
Ni2+-NTA-agarose purification, a c-myc epitope, and a
nonapeptide consensus sequence for tyrosine sulfation (22). The
cDNA sequence encoding the signal peptide of gp40 was exchanged by
the sequence encoding the signal and the HMY tag from
MPR46HMY (23) (provided by C. Itin, Stanford University).
For this purpose, an in-frame KpnI site was introduced at
the 3' end of the triple tag sequence and at the 5' end of the sequence
encoding the mature sequence of gp40 by PCR. The two segments were
ligated at the KpnI site and introduced into the expression
plasmid pCB6 and the retroviral shuttle vector pMX-IRES (24) (from J. Bogan and H. F. Lodish, Whitehead Institute, Cambridge, MA). MDCK
I cells were transfected with LipofectAMINE (Invitrogen). Clonal cell lines resistant to 0.8 mg/ml G418-sulfate (Geneticin; Invitrogen) were
isolated and screened for expression of gp40HMY by
metabolic labeling with [35S]methionine followed by
Ni2+-NTA-agarose purification according to the
manufacturer's protocol (Qiagen), SDS-gel electrophoresis, and
fluorography or phosphorimaging. For expression in MDCK II cells, we
took advantage of a MDCK II cell line (MDCK IIeco) stably expressing
the murine ecotropic receptor for Moloney murine leukemia virus
particles, which was prepared by transfecting MDCK II cells with
pIRESeco-neo (from J. Bogan) and selecting for resistance to
G418-sulfate (Invitrogen). Virus particles were produced by
transfection of NX-Eco cells, virus-free helper cells obtained form
J. Nolan (Stanford University), with pMX-gp40HMY.
Metabolic Labeling and Analysis of 9-O-Acetylated
Proteins--
Metabolic labeling with [35S]methionine or
[35S]sulfate was performed as described previously (22).
Cells were labeled for 1 h at 37 °C, lysed, and subjected to
precipitation with Ni2+-NTA-agarose, lectin-agarose, or
CHE-FcD on protein A-Sepharose. Five µg of CHE-FcD prebound to 20 µl of packed protein A-Sepharose beads were added per sample. The
suspensions were incubated overnight at 4 °C with end-over-end
rotation. The beads were washed twice in lysis buffer and once in PBS
and finally boiled in gel loading buffer containing reducing agent. The
eluate was separated by SDS-gel electrophoresis and analyzed by
fluorography. The biotinylated lectins Maackia amurensis
hemagglutinin (MAH, sold as MAL-II by Vector Laboratories; 5 µg/sample) and Sambucus nigra agglutinin (SNA; Vector
Laboratories; 10 µg/sample) were coupled to avidin-agarose (Pierce;
10 µl packed beads/sample) for lectin precipitation.
As a control, the 9-O-acetyl modification was hydrolyzed by
mild base treatment by the addition of 0.1 M NaOH to the
samples, incubation for 15 min at 37 °C, and neutralization with
HCl. To test for membrane integration of sgp50,
[35S]sulfate-labeled cells were subjected to saponin or
alkaline extraction (25, 26) before precipitation with CHE-FcD. To block N-glycosylation, cells were preincubated for 4 h
and [35S]sulfate-labeled in the presence of 5 µg/ml
tunicamycin (Sigma). Complete inhibition of N-glycosylation
was confirmed in a parallel analysis of MDCK II cells expressing the
asialoglycoprotein receptor H1 (data not shown).
To remove N-glycans, CHE-FcD precipitates were suspended in
100 µl of 0.1 M sodium phosphate, pH 6.8, containing 50 mM EDTA, 1% -mercaptoethanol, and 0.1% SDS and boiled
for 5 min. After the addition of Nonidet P-40 to a final concentration
of 1%, samples were incubated with 0.25 unit of endoglycosidase
F/N-glycosidase F (Roche Biochemicals) for 3 h at 37 °C.
Samples were then analyzed directly or after a second precipitation
with CHE-FcD. To test for O-glycosylation of sgp50, CHE-FcD
precipitates were incubated with 5 milliunits of neuraminidase from
Arthrobacter ureafasciens for 4 h at 37 °C in 50 mM sodium acetate, pH 5.5, followed by incubation with 1.25 milliunits of O-glycosidase (both from Roche Biochemicals)
after the addition of 75 mM potassium phosphate, pH 7.4, overnight at 37 °C. To test for the presence of chondroitin sulfate
chains, [35S]sulfate-labeled gp40HMY isolated
from a 35-mm well of gpHMY expressing MDCK I cells
was purified on Ni2+-NTA-agarose and incubated on the beads
with or without 0.2 unit of chondroitinase ABC (Fluka) in 100 µl of
33 mM Tris acetate, 66 mM potassium acetate, 10 mM magnesium acetate, and 0.5 mM
dithiothreitol, pH 7.9, for 3 h at 37 °C. The samples were then
boiled with SDS-gel sample buffer and analyzed.
To suppress glycosaminoglycan synthesis or sialylation of
O-linked glycans, cells were incubated for 18 h with 2 mM 4-methylumbelliferyl -D-xyloside or 10 mM benzyl
2-acetamido-2-deoxy- -D-galactopyranoside (benzyl-GalNAc;
both from Sigma), respectively (27, 28). Cells were then labeled with
[35S]sulfate for 1 h and analyzed by precipitation
with Ni2+-NTA-agarose or CHE-FcD gel electrophoresis
and fluorography. To analyze sgp50, the cells were incubated with
tunicamycin before and during labeling as described above to inhibit
N-glycosylation.
 |
RESULTS |
Intracellular 9-O-Acetylated Sialic Acid Detected with CHE-FcD
Fluorescence Microscopy--
CHE-Fc, the fusion protein of influenza C
virus hemagglutinin-esterase with the constant region of human IgG,
efficiently binds to 9-O-acetylated sialic acid if the
esterase is inactivated by diisopropyl fluorophosphate treatment (20).
We have used the resulting CHE-FcD as a probe for fluorescence
microscopy in combination with a fluorescein isothiocyanate-labeled
anti-human IgG antibody on MDCK I and II cells (Fig.
1). Previous studies using whole
influenza C virions have shown that MDCK I cells contain abundant
9-O-acetylated sialoglycoconjugates on their surface, mediating efficient infection, whereas the closely related MDCK II
cells do not (13). As shown in Fig. 1A, unpermeabilized MDCK I cells were strongly labeled by CHE-FcD on the cell surface. Upon
permeabilization, additional perinuclear staining became apparent (Fig.
1B), most likely corresponding to the
trans-Golgi, where 9-O-acetylation takes place.
The specificity of staining for 9-O-acetyl sialic acids was
demonstrated using CHE-Fc with the active esterase (Fig.
1C): as the esterase hydrolyzed the 9-O-acetyl
esters, staining was eliminated. Consistent with the experiments using
viral infection, MDCK II cells were completely negative for CHE-FcD
staining at the plasma membrane (Fig. 1E). In permeabilized
cells, however, a strong perinuclear signal was discovered (Fig.
1F), which was specific for 9-O-acetylation
because it was eliminated when untreated CHE-Fc was used (Fig.
1G). Even when the cells were fixed with methanol and
acetone under conditions that have been shown to extract glycolipids
(21), the labeling pattern was retained, indicating that the molecules
detected by CHE-FcD are primarily glycoproteins.

View larger version (81K):
[in this window]
[in a new window]
|
Fig. 1.
Detection of 9-O-acetylated
sialoglycoconjugates by fluorescence microscopy using CHE-FcD.
MDCK I (A-D) and II cells (E-H) were fixed with
paraformaldehyde and permeabilized with Triton X-100 (B, C,
F, and G) or not permeabilized (A and
E). To detect 9-O-acetyl sialic acid, the cells
were stained with CHE-FcD (A, B, E, and F) and a
fluorescent antibody against the Fc portion of the probe. As a control
for specificity, the cells in C and G were
stained with CHE-Fc, in which the acetyl esterase was not inactivated
by diisopropyl fluorophosphate treatment. In D and
H, the cells were fixed with methanol and acetone to extract
glycolipids and then stained with CHE-FcD. Bar, 20 µm.
|
|
A similar staining pattern was observed in a variety of different cell
lines derived from different tissues and species (Table I and Fig.
2). None of these cell lines showed any
detectable CHE-FcD labeling at the cell surface, yet all of them showed
perinuclear staining. Intracellular 9-O-acetylation of
sialoglycoconjugates is thus a very common, if not ubiquitous,
modification.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 2.
Intracellular CHE-FcD staining in
BHK-21 (A), HEK-293 (B), and COS-7
(C) cells. The cells were fixed with
paraformaldehyde, permeabilized with Triton X-100, and stained with
CHE-FcD. Bar, 40 µm.
|
|
The intracellular staining pattern is reminiscent of the Golgi
apparatus. To test this directly, calf primary aortic endothelial cells
were colabeled with CHE-FcD and an antibody against the Golgi marker
giantin (29). Both probes stained the same structures (Fig.
3, A and B). Even
upon incubation with brefeldin A, which causes a dramatic
redistribution of Golgi elements (30), the labeling pattern of both
probes was affected in an identical manner (Fig. 3, C and
D).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Localization of intracellular
9-O-acetyl sialic acid to the Golgi. Calf primary
aortic endothelial cells were incubated with (C and
D) or without brefeldin A (A and B),
fixed and permeabilized, and costained with CHE-FcD and a monoclonal
antibody against the Golgi protein giantin followed by appropriate
fluorescent secondary antibodies. Bar, 40 µm.
|
|
Identification of a Sulfated 9-O-Acetylated Glycoprotein of 50 kDa--
To visualize 9-O-acetylated glycoproteins,
proteins in cell lysates were subjected to SDS-gel electrophoresis,
transferred to polyvinylidene difluoride membranes, and probed with
CHE-FcD (Fig. 4). As a control for
specificity, half the samples were treated with mild base (0.1 M NaOH for 15 min at 37 °C) before analysis, which is
sufficient to hydrolyze the O-acetyl groups on sialic acid.
Accordingly, bovine submaxillary mucin, an established 9-O-acetylated sialoglycoprotein, was recognized by CHE-FcD
before but not after mild base treatment (Fig. 4, lanes 1 and 2). In MDCK I cells (Fig. 4, lanes 7 and
8), the major 9-O-acetylated protein has a
molecular mass of ~40 kDa, corresponding to gp40, the major influenza
C virus receptor at the cell surface (13, 14). In addition, a second
specific band with an apparent molecular mass of ~50 kDa could be
detected. Proteins with the same electrophoretic mobility were also
observed in MDCK II and HEK-293 cells (Fig. 4, lanes 3-6),
where they constitute the predominant 9-O-acetylated protein. Additional weak bands were not sensitive to mild base treatment and thus constitute unspecific signals.

View larger version (85K):
[in this window]
[in a new window]
|
Fig. 4.
Detection of 9-O-acetyl
sialoglycoproteins by Western analysis using CHE-FcD. Cell lysates
from HEK-293 and MDCK I and II cells were treated with mild base (+ NaOH) to deacetylate sialic acids or mock-treated (-). The proteins
were separated by SDS-gel electrophoresis, immobilized, and probed for
9-O-acetylated sialic acid using CHE-FcD, followed by
horseradish peroxidase-conjugated anti-human IgG and chemiluminescence
detection. Bovine submaxillary mucin (BSM) was used as a
positive control. The positions of marker proteins are indicated with
their molecular masses in kDa.
|
|
As an alternative detection method, CHE-FcD coupled to protein
A-Sepharose was used to directly precipitate 9-O-acetylated proteins from metabolically labeled cells. Using
[35S]methionine for labeling led to considerable
nonspecific background (data not shown). However, when cells were
labeled with [35S]sulfate, the pattern of radioactive
proteins specifically precipitated with CHE-FcD was strikingly simple
(Fig. 5). In all cell lines tested, a
single major sulfated protein of ~50 kDa was detected (Fig. 5,
lanes 1-12; Table I), which may correspond to the major 50-kDa protein detected by CHE-FcD on Western blots (Fig. 4). This
protein was called sgp50 (for sulfated glycoprotein of 50 kDa).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 5.
Identification of a sulfated
9-O-acetylated glycoprotein of 50 kDa. The
indicated cell lines were labeled with [35S]sulfate,
lysed, and treated with mild base (+ NaOH) to deacetylate sialic acids
or mock-treated (-) (lanes 1-12).
9-O-Acetylated sialoglycoproteins were then isolated using
CHE-FcD and protein A-Sepharose and analyzed by SDS-gel electrophoresis
and fluorography. To test for membrane integration, labeled HEK-293
cells were subjected to alkaline extraction (Alk.) and
separation into a membrane pellet (P) and a supernatant
(S) (lanes 13 and 14). Alternatively,
the labeled cells were extracted with 0.1% saponine (Sap.)
and separated into a soluble saponin extract (S) and the
rest of the cells (C). The fractions were analyzed as
described above. The arrowhead indicates the 50 kDa
position.
|
|
To test whether sgp50 is a membrane protein,
[35S]sulfate-labeled HEK-293 cells were extracted with
0.1% saponin (Fig. 5, lanes 15 and 16), which
allows soluble polypeptides to be released into the medium, whereas the
membranes remain sufficiently intact to retain integrated proteins
(26). Alternatively, the labeled cells were subjected to alkaline
extraction, which solublilizes even peripheral proteins, whereas
integral membrane proteins remain pelletable with the membranes (Fig.
5, lanes 13 and 14). With both procedures, sgp50
remained with the membranes and was not released into the supernatant,
indicating that it is an integral membrane protein.
gp40 and sgp50 Are 9-O-Acetylated by Different
Machineries--
MDCK II cells and other cell lines may lack
9-O-acetyl sialic acids in the plasma membrane because they
do not express plasma membrane substrates for 9-O-acetyl
transferase. To test this possibility, gp40, the major
9-O-acetylated glycoprotein of MDCK I cells, was expressed
in some of these cell lines. To allow simultaneous analysis of gp40 and
endogenous sgp50 by 35S sulfation, we modified the amino
terminus of gp40 on the DNA level by adding a triple tag sequence
consisting of a His6 sequence for
Ni2+-NTA-agarose purification, a c-myc epitope, and a
nonapeptide consensus sequence for tyrosine sulfation (22, 23). The
tagged protein, gp40HMY, was expressed in MDCK I and MDCK
II cells. The cells were labeled with [35S]sulfate and
subjected to different isolation procedures followed by gel
electrophoresis and fluorography (Fig.
6A). gp40HMY was
expressed in both cell lines to a similar extent as shown by
Ni2+-NTA-agarose precipitation (Fig. 6A, lanes 1 and 2). As expected, 35S-sulfated
gp40HMY was 9-O-acetylated in MDCK I cells and
thus isolated with CHE-FcD like sgp50 (Fig. 6A, lane
3). In MDCK II cells, however, only sgp50, and not
gp40HMY, was recognized by CHE-FcD (Fig. 6A,
lane 4). The machinery for 9-O-acetylation of
sgp50 therefore does not recognize gp40. The same negative result was
also obtained in transfected COS-7 cells (Fig 6A, lanes 5 and 6), where gp40HMY runs with slightly lower
mobility, probably due to different glycosylation.

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 6.
gp40HMY is
9-O-acetylated in MDCK I and CHO cells, but not in
MDCK II or COS-7 cells. A, MDCK I and II, CHO-K1, and
COS-7 cells expressing gp40HMY were labeled with
[35S]sulfate, lysed, and incubated with
Ni2+-NTA-agarose (Ni) or CHE-FcD/protein
A-Sepharose (CHE) to isolate gp40HMY or
glycoproteins with 9-O-acetyl sialic acids, respectively
(lanes 1-6). In the case of COS-7 cells,
Ni2+-NTA-agarose and CHE-FcD purification were
performed successively. The positions of sgp50 and gp40 are indicated.
The arrow points at the heterogeneous high molecular weight
forms of gp40HMY. B, to analyze the nature of
the high molecular weight forms of gp40HMY,
[35S]sulfate-labeled gp40HMY from
gp40HMY-expressing MDCK II cells was isolated with
Ni2+-NTA-agarose (Ni) and then incubated with
(Ch) or without (-) chondroitinase before SDS-gel
electrophoresis and fluorography. The ~90-kDa band
(asterisk) most likely represents covalent dimers of
gp40HMY generated by oxidation during chondroitinase
incubation. The positions of sgp50 and gp40 are indicated.
|
|
Does differential 9-O-acetylation of gp40 and sgp50
correlate with a major difference in glycosylation of the two
substrates? To answer this question, we analyzed the two model
substrates with respect to the presence of N- or
O-glycosylation and the linkages of their sialic acids. gp40
is a mucin-like protein with extensive O-linked
glycosylation, but without N-linked glycans (13, 14). On our
gels, we always observed a diffuse signal around 70-120 kDa
(arrow in Fig. 6, A and B) in addition
to the compact band of 40 kDa when gp40 or gp40HMY was
isolated. When gp40HMY expressed in MDCK I cells was
labeled with [35S]sulfate, purified using
Ni2+-NTA-agarose, and incubated with chondroitinase, the
diffuse band collapsed into the 40-kDa band (Fig. 6B, lane
2), indicating that a fraction of the proteins carried chondroitin
sulfate chains. However, 9-O-acetylation of
gp40HMY was obviously independent of glycosaminoglycan
addition (Fig. 6A, lane 3).
To test sgp50 for O-linked glycans, sgp50 was first
precipitated with CHE-FcD from [35S]sulfate-labeled MDCK
I cells (Fig. 7A, lane 1),
desialylated (lane 2), and then incubated with
O-glycosidase (lane 3). A shift in mobility upon
SDS-gel electrophoresis indicated the presence of O-glycans.
Similarly, labeled sgp50 precipitated with CHE-FcD was incubated with
or without endoglycosidase F and analyzed either directly (Fig.
7A, lanes 4 and 5) or after a second CHE-FcD
precipitation (lanes 6 and 7). Endoglycosidase F
digestion produced two forms with increased electrophoretic mobility,
indicating the presence of at least two N-linked glycans in
sgp50. Even the lowest of the two forms was still recognized by CHE-FcD
and thus carried 9-O-acetyl sialic acid (Fig. 7A,
lane 7). As an alternative approach, MDCK II cells were
labeled with [35S]sulfate in the presence of tunicamycin
under conditions that completely inhibit N-glycosylation.
Using CHE-FcD, a 9-O-acetylated form of sgp50 was
precipitated with a mobility identical to that of the lowest
endoglycosidase F digestion product (Fig. 7A, lane 9). These results show that sgp50 carries both N- and
O-linked glycans and suggest that the O-linked
glycans contain 9-O-acetylated sialic acid.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 7.
Characterization of glycans on
gp40HMY and sgp50 in MDCK cells. A,
9-O-acetylated proteins of
[35S]sulfate-labeled MDCK I cells were isolated with
CHE-FcD/protein A-Sepharose, desialylated by incubation with
neuraminidase (Neu), and incubated with
O-glycosidase (OG; lanes 1-3).
Alternatively, CHE-FcD-precipitated labeled proteins were boiled in
SDS, incubated without (-) or with endoglycosidase F (EF),
and analyzed immediately (lanes 4 and 5) or after
a second CHE-FcD precipitation (lanes 6 and 7).
To block N-glycosylation, MDCK II cells were treated with
(Tu) or without (-) tunicamycin, labeled with
[35S]sulfate, lysed, and subjected to precipitation with
CHE-FcD/protein A-Sepharose, MAH-agarose, or SNA-agarose (lanes
8-13) before SDS-gel electrophoresis and fluorography. (A small
amount of full-size sgp50 is often detected in the tunicamycin-treated
sample, most likely corresponding to molecules that were synthesized
before incubation with the inhibitor and incorporated
[35S]sulfate during the labeling period.) B,
MDCK I and II cells expressing gp40HMY were labeled with
[35S]sulfate, lysed, and incubated with MAH-agarose or
SNA-agarose (lanes 1-4). From other MDCK I lysates,
9-O-acetylated proteins were first isolated with
CHE-FcD/protein A-Sepharose and then released by mild base treatment
and subjected to a second isolation with MAH-agarose or SNA-agarose or
to no further treatment (-) (lanes 5-7). The positions of
sgp50 and gp40 are indicated. The circles indicate
unrelated, sulfated proteins with 2-6-linked sialic acids.
|
|
To analyze gp40 and sgp50 with respect to the most common linkages of
sialic acids, MDCK I and MDCK II cells expressing gp40HMY
were labeled with [35S]sulfate, lysed, and subjected to
lectin precipitation. We used either MAH, which specifically recognizes
sialic acids linked 2-3 to Gal in the O-linked sequence
Sia 2-3Gal 1-3(±Sia 2-6)GalNAc (31, 32), or SNA, which
recognizes Sia 2-6Gal of N-glycans or O-linked
Sia 2-6GalNAc (33). gp40HMY and sgp50 were both
precipitated with MAH, either directly from cell lysates (Fig.
7B, lanes 1 and 2) or after initial purification with CHE-FcD (lane 6). In contrast, a labeled protein of 50 kDa, but none of 40 kDa, was precipitated with SNA along with several proteins of other sizes from both MDCK I and MDCK II cells (Fig. 7B, lanes 3 and 4). gp40 in MDCK I cells was
previously shown not to be recognized by SNA (13). The identity of the
50-kDa protein with the 9-O-acetylated sgp50 was confirmed
by successive precipitation with CHE-FcD and SNA (Fig. 7B, lane
7). sgp50 synthesized in MDCK II cells treated with tunicamycin
and thus lacking N-glycans was still recognized by MAH (Fig.
7A, lane 11) but was not precipitated with SNA (lane
13). Likewise, all other SNA-positive sulfate-labeled glycoproteins were not precipitated any more after tunicamycin treatment, demonstrating the presence of 2-6-linked sialic acid in
N-linked glycans.
These findings could be confirmed using the CHO cell lines CHO-K1 and
CHO-Lec1. CHO cells are known to lack 2-6-linked sialic acid in
N-glycans (34, 35). In addition, CHO-Lec1 mutant cells are
unable to synthesize hybrid-type and complex N-glycans due to a defect in N-acetylglucosaminyltransferase I (36, 37) and stop at Man9GlcNAc2 structures. Upon
[35S]sulfate labeling and precipitation using CHE-FcD,
sgp50 of its normal size and an additional sulfated protein of slightly
less than 40 kDa were detected in CHO-K1 cells (Fig.
8, lane 1). In CHO-Lec1 cells,
sgp50 was still recognized but shifted to a position of reduced
molecular mass (lane 2).

View larger version (74K):
[in this window]
[in a new window]
|
Fig. 8.
Glycosylation of sgp50 in CHO cells.
CHO-K1 cells and CHO-Lec1 cells, which lack sialic acids on
N-glycans, were labeled with [35S]sulfate,
lysed, and subjected to precipitation with CHE-FcD/protein A-Sepharose,
MAH-agarose, or SNA-agarose. Samples were analyzed by SDS-gel
electrophoresis and fluorography. The positions of sgp50 and gp40 are
indicated. The open circle indicates a second sulfated
9-O-acetylated glycoprotein of ~38 kDa in CHO cells. The
closed circles indicate two unrelated MAH-positive sulfated
glycoproteins.
|
|
To show more directly that 9-O-acetylation occurred on
O-glycans in both gp40 and sgp50, cells were treated with
either benzyl-GalNAc to inhibit sialylation on O-glycans
(27) or -D-xyloside to block glycosaminoglycan synthesis
on proteins (28). Treatment of MDCK I cells expressing
gp40HMY with benzyl-GalNAc did not affect synthesis of
gp40HMY or its mobility upon gel electrophoresis, as judged
by precipitation with Ni2+-NTA-agarose (Fig.
9, lanes 1 and 2).
Removal of sialic acid has previously been observed not to alter its
electrophoretic mobility (13). However, both the 40-kDa band and the
form carrying chondroitin sulfate chains were not recognized by CHE-FcD
any more (Fig. 9, lane 4 versus lane 3),
indicating that normally 9-O-acetylation takes place on
sialic acids of O-glycans. -D-Xyloside, in
contrast, strongly reduced the chondroitin sulfate chains of
gp40HMY, but not the ability of the 40-kDa protein to be
recognized by CHE-FcD (Fig. 9, lanes 5-8). The same result
was obtained for sgp50 in MDCK I cells that were treated in addition
with tunicamycin before and during [35S]sulfate labeling
to analyze sgp50 in the absence of N-glycans and shift the
newly synthesized proteins away from preexisting ones that might be
further sulfated during the labeling period (Fig. 9, lanes
9-12). Recognition by CHE-FcD was strongly inhibited by
benzyl-GalNAc (Fig. 9, lane 10) but was not affected by
-D-xyloside (lane 12).

View larger version (79K):
[in this window]
[in a new window]
|
Fig. 9.
9-O-Acetylation of
O-linked sialic acid in both gp40 and sgp50. MDCK
I cells expressing gp40HMY (lanes 1-8) or
normal MDCK I cells (lanes 9-12) were incubated for 18 h with or without benzyl-GalNAc (G) or 4-methylumbelliferyl
xyloside (X) to inhibit sialylation of O-glycans
or synthesis of glycosaminoglycans, respectively. The cells were then
labeled with [35S]sulfate, lysed, and subjected to
precipitation with CHE-FcD/protein A-Sepharose or
Ni2+-NTA-agarose. To test the effect on sgp50 in the
absence of N-glycans (sgp50-N), the cells in
lanes 9-12 were treated with tunicamycin (Tu)
before and during labeling.
|
|
Together, the results demonstrate the presence of 2-3-linked sialic
acid on O-linked glycans of both gp40 and sgp50, whereas only sgp50 contains Sia 2-6Gal. However, both gp40 and sgp50 are 9-O-acetylated on sialic acids of O-linked
glycans. The difference between gp40 and sgp50 that is responsible for
their differential 9-O-acetylation is therefore more subtle
than the presence or absence of N-linked glycosylation.
 |
DISCUSSION |
CHE-FcD has proven to be a valuable tool to detect
9-O-acetylated glycoconjugates in a variety of methods. In
the present study, we have used it for the first time in fluorescence
microscopy and discovered significant intracellular
9-O-acetylation of sialoglycoproteins in cell lines
previously considered to lack this modification. MDCK II and
BHK-21 cells were shown to be devoid of
9-O-acetylated cell surface proteins by influenza C virus
binding or infection assays (10, 13), whereas CHO and BHK-21 cells
scored negative in flow cytometry experiments using CHE-FcD (35). Our
results are consistent with these studies because in all four cell
lines, CHE-FcD staining is restricted to a perinuclear structure
corresponding to the Golgi, most likely the trans-Golgi
network, and is absent from the plasma membrane. This intracellular
9-O-acetylation is remarkably ubiquitous because it was
detected in all 12 cell lines we tested, which were derived from
different species and tissues (Table I).
It is not surprising per se that 9-O-acetylated
proteins can be detected in the Golgi because this modification has
previously been shown to occur in Golgi membranes of rat liver (38,
39), more precisely in a compartment of the trans-Golgi
network separate from the compartment of sialylation (11). Secretory
and plasma membrane proteins thus pass through this compartment and may
acquire 9-O-acetylation as one of the last modifications
before arrival at the cell surface. The known functions of
9-O-acetylation in cell-cell and host-pathogen interactions
as well as the relative abundance of 9-O-acetyl sialic acids
in secretory proteins (20) pointed to a predominantly extracellular
role of this modification. The striking presence of
9-O-acetylated proteins in the Golgi and their absence from
the cell surface also suggest an intracellular function.
Western analysis revealed a major 9-O-acetylated
glycoprotein of ~50 kDa in HEK-293 and MDCK II cells, which was also
prominently present in MDCK I cells besides gp40. Using sulfate
labeling, a sulfated membrane protein of the same size, sgp50, could be precipitated with CHE-FcD in all cell lines analyzed. Because sulfation
yielded good sensitivity and low background, sgp50 and gp40 tagged with
a sulfation site (gp40HMY) were useful tools to analyze the
glycosylation characteristics of these two 9-O-acetylation substrates.
The simplest explanation for the absence of 9-O-acetylated
proteins on the surface of a cell line is that the cells do not express
substrates that are transported to the plasma membrane. However,
gp40HMY, which is modified in MDCK I cells, was not
acetylated when expressed in MDCK II and COS-7 cells. The
9-O-acetyl transferase responsible for acetylation of the
Golgi-resident substrate(s) apparently does not recognize gp40 as a
substrate. There are thus two distinct 9-O-acetylation
machineries: a ubiquitous one with mainly intracellular substrates
including sgp50, and a second one present in MDCK I cells that
recognizes gp40. In MDCK II and COS-7 cells, this latter machinery and
its substrate gp40 are missing.
Previously, it has been shown that 9-O-acetyl transferases
can have clear linkage specificity. CHO-K1 cells, which lack
2-6-linked sialic acids on N-linked glycans (34) and do
not bind CHE-FcD at the plasma membrane, presented
9-O-acetyl sialic acid on the cell surface upon expression
of the 2-6 sialyltransferase for N-glycans (ST6Gal I),
but not when the competing 2-3 sialyltransferase (ST3Gal III) was
transfected (35). The parental CHO cells thus have a
9-O-acetyl transferase for N-linked Sia 2-6Gal
but essentially no corresponding substrates. This transferase is
therefore not a candidate enzyme for the 9-O-acetylation of
sgp50 or gp40. There are thus at least three distinct
9-O-acetylation machineries for glycoproteins, modifying
gp40, sgp50, or N-linked Sia 2-6Gal, respectively.
gp40 and sgp50 are 9-O-acetylated on O-linked
glycans. Because both proteins are recognized by MAH, they positively
contain sialylated core 1 structures, i.e.
Sia 2-3Gal 1-3GalNAc and/or Sia 2-3Gal 1-3(Sia 2-6)GalNAc, most probably in addition to
other structures for which there is no direct evidence at present.
Considering the high specificity of 9-O-acetylation as
observed for example in MDCK I and II cells, substrate recognition of
9-O-acetyl transferases must reach beyond the sialic acid
and its linkage and must include more extended, possibly rare glycan
structures and/or contributions from the protein core. Our findings
indicate that 9-O-acetylation is more widespread than
previously known and may also have intracellular functions.
 |
ACKNOWLEDGEMENTS |
We thank Drs. G. Herrler, A. Varki, J. Bogan,
H. F. Lodish, J. Nolan, C. Itin, H. P. Hauri, and K. Fiedler
for reagents and cell lines and Dr. Ajit Varki for critical reading of
the manuscript.
 |
FOOTNOTES |
*
This work was supported by Grant 31-061579.00 from the Swiss
National Science Foundation.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 41-61-267-2164;
Fax: 41-61-267-2149; E-mail: Martin.Spiess@unibas.ch.
Published, JBC Papers in Press, March 19, 2002, DOI 10.1074/jbc.M109408200
 |
ABBREVIATIONS |
The abbreviations used are:
MDCK, Madin-Darby
canine kidney;
PBS, phosphate-buffered saline;
SNA, Sambucus
nigra agglutinin;
CHO, Chinese hamster ovary;
Ni2+-NTA, nickel-nitrilotriacetic acid;
MAH, Maackia
amurensis hemagglutinin;
GalNAc, N-acetylglucosamine.
 |
REFERENCES |
| 1.
|
Varki, A.
(1992)
Glycobiology
2,
25-40[Free Full Text]
|
| 2.
|
Schauer, R.
(1991)
Glycobiology
1,
449-452[Free Full Text]
|
| 3.
|
Varki, A.
(1997)
FASEB J.
11,
248-255[Abstract]
|
| 4.
|
Varki, A.
(1998)
Trends Cell Biol.
8,
34-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Sjoberg, E. R.,
Powell, L. D.,
Klein, A.,
and Varki, A.
(1994)
J. Cell Biol.
126,
549-562[Abstract/Free Full Text]
|
| 6.
|
Varki, A.,
Hooshmand, F.,
Diaz, S.,
Varki, N. M.,
and Hedrick, S. M.
(1991)
Cell
65,
65-74[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Rogers, G. N.,
Herrler, G.,
Paulson, J. C.,
and Klenk, H. D.
(1986)
J. Biol. Chem.
261,
5947-5951[Abstract/Free Full Text]
|
| 8.
|
Schultze, B.,
and Herrler, G.
(1992)
J. Gen. Virol.
73,
901-906[Abstract/Free Full Text]
|
| 9.
|
Schultze, B.,
and Herrler, G.
(1993)
Adv. Exp. Med. Biol.
342,
299-304[Medline]
[Order article via Infotrieve]
|
| 10.
|
Herrler, G.,
and Klenk, H. D.
(1987)
Virology
159,
102-108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Chammas, R.,
McCaffery, J. M.,
Klein, A.,
Ito, Y.,
Saucan, L.,
Palade, G.,
Farquhar, M. G.,
and Varki, A.
(1996)
Mol. Biol. Cell
7,
1691-1707[Abstract]
|
| 12.
|
Krishna, M.,
and Varki, A.
(1997)
J. Exp. Med.
185,
1997-2013[Abstract/Free Full Text]
|
| 13.
|
Zimmer, G.,
Klenk, H. D.,
and Herrler, G.
(1995)
J. Biol. Chem.
270,
17815-17822[Abstract/Free Full Text]
|
| 14.
|
Zimmer, G.,
Lottspeich, F.,
Maisner, A.,
Klenk, H. D.,
and Herrler, G.
(1997)
Biochem. J.
326,
99-108
|
| 15.
|
Herrler, G.,
Durkop, I.,
Becht, H.,
and Klenk, H. D.
(1988)
J. Gen. Virol.
69,
839-846[Abstract/Free Full Text]
|
| 16.
|
Muchmore, E. A.,
Varki, N. M.,
Fukuda, M.,
and Varki, A.
(1987)
FASEB J.
1,
229-235[Abstract]
|
| 17.
|
Zimmer, G.,
Reuter, G.,
and Schauer, R.
(1992)
Eur. J. Biochem.
204,
209-215[Medline]
[Order article via Infotrieve]
|
| 18.
|
Zimmer, G.,
Suguri, T.,
Reuter, G., Yu, R. K.,
Schauer, R.,
and Herrler, G.
(1994)
Glycobiology
4,
343-349[Abstract/Free Full Text]
|
| 19.
|
Harms, G.,
Reuter, G.,
Corfield, A. P.,
and Schauer, R.
(1996)
Glycoconj. J.
13,
621-630[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Klein, A.,
Krishna, M.,
Varki, N. M.,
and Varki, A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7782-7786[Abstract/Free Full Text]
|
| 21.
|
Schwarz, A.,
and Futerman, A. H.
(1997)
J. Histochem. Cytochem.
45,
611-618[Abstract/Free Full Text]
|
| 22.
|
Leitinger, B.,
Brown, J. L.,
and Spiess, M.
(1994)
J. Biol. Chem.
269,
8115-8121[Abstract/Free Full Text]
|
| 23.
|
Itin, C.,
Rancano, C.,
Nakajima, Y.,
and Pfeffer, S. R.
(1997)
J. Biol. Chem.
272,
27737-27744[Abstract/Free Full Text]
|
| 24.
|
Liu, X.,
Constantinescu, S. N.,
Sun, Y.,
Bogan, J. S.,
Hirsch, D.,
Weinberg, R. A.,
and Lodish, H. F.
(2000)
Anal. Biochem.
280,
20-28[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Gilmore, R.,
and Blobel, G.
(1985)
Cell
42,
497-505[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Wessels, H. P.,
Beltzer, J. P.,
and Spiess, M.
(1991)
Methods Cell Biol.
34,
287-302[Medline]
[Order article via Infotrieve]
|
| 27.
|
Lohmander, L. S.,
Hascall, V. C.,
and Caplan, A. I.
(1979)
J. Biol. Chem.
254,
10551-10561[Abstract/Free Full Text]
|
| 28.
|
Huet, G.,
Hennebicq-Reig, S.,
de Bolos, C.,
Ulloa, F.,
Lesuffleur, T.,
Barbat, A.,
Carriere, V.,
Kim, I.,
Real, F. X.,
Delannoy, P.,
and Zweibaum, A.
(1998)
J. Cell Biol.
141,
1311-1322[Abstract/Free Full Text]
|
| 29.
|
Linstedt, A. D.,
and Hauri, H. P.
(1993)
Mol. Biol. Cell
4,
679-693[Abstract]
|
| 30.
|
Lippincott-Schwartz, J.,
Donaldson, J. G.,
Schweizer, A.,
Berger, E. G.,
Hauri, H. P.,
Yuan, L. C.,
and Klausner, R. D.
(1990)
Cell
60,
821-836[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Konami, Y.,
Yamamoto, K.,
Osawa, T.,
and Irimura, T.
(1994)
FEBS Lett.
342,
334-338[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Yim, M.,
Ono, T.,
and Irimura, T.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
2222-2225[Abstract/Free Full Text]
|
| 33.
|
Shibuya, N.,
Goldstein, I. J.,
Broekaert, W. F.,
Nsimba-Lubaki, M.,
Peeters, B.,
and Peumans, W. J.
(1987)
J. Biol. Chem.
262,
1596-1601[Abstract/Free Full Text]
|
| 34.
|
Lee, E. U.,
Roth, J.,
and Paulson, J. C.
(1989)
J. Biol. Chem.
264,
13848-13855[Abstract/Free Full Text]
|
| 35.
|
Shi, W. X.,
Chammas, R.,
and Varki, A.
(1996)
J. Biol. Chem.
271,
15130-15138[Abstract/Free Full Text]
|
| 36.
|
Robertson, M. A.,
Etchison, J. R.,
Robertson, J. S.,
Summers, D. F.,
and Stanley, P.
(1978)
Cell
13,
515-526[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Puthalakath, H.,
Burke, J.,
and Gleeson, P. A.
(1996)
J. Biol. Chem.
271,
27818-27822[Abstract/Free Full Text]
|
| 38.
|
Diaz, S.,
Higa, H. H.,
Hayes, B. K.,
and Varki, A.
(1989)
J. Biol. Chem.
264,
19416-19426[Abstract/Free Full Text]
|
| 39.
|
Butor, C.,
Diaz, S.,
and Varki, A.
(1993)
J. Biol. Chem.
268,
10197-10206[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Satake, H. Y. Chen, and A. Varki
Genes Modulated by Expression of GD3 Synthase in Chinese Hamster Ovary Cells. EVIDENCE THAT THE Tis21 GENE IS INVOLVED IN THE INDUCTION OF GD3 9-O-ACETYLATION
J. Biol. Chem.,
February 28, 2003;
278(10):
7942 - 7948.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|